Replicative senescence and the Hayflick limit: telomere mechanism

Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.

Definition

Category: Cell-fate outcome

Also known as: Hayflick limit, replicative senescence, telomere-driven senescence

Normal human somatic cells can divide only a finite number of times (the Hayflick limit) before entering replicative senescence — a stable growth arrest. Progressive telomere shortening is a principal counter for this limit: when telomeres become critically short, the end is sensed as DNA damage and the cell arrests or dies. This links telomere biology directly to the senescence field.

Key points

Critically short telomeres trigger a persistent DNA-damage response that drives senescence or apoptosis — the mechanistic bridge between telomere length and cell fate.
Replicative senescence is one route into the senescent state; senescence biology and senolytics are covered in depth on senesiq.com and are cross-referenced here, not duplicated.
Because senescence has tumour-suppressive roles, indefinitely postponing it by lengthening telomeres is not unambiguously beneficial.

Sourcing

Standard senescence/Hayflick reviews (Hayflick; Campisi). Senescence pharmacology cross-referenced to senesiq.com. Review-level description.

Reference synthesis (tier 4); verification: review_level_2026-07-12.